Courtesy of Dr. Carlos Fava. When it comes to severe unprotected left main distal bifurcation lesions, surgery continues to be the preferred treatment option. However, due to the growing number of patients that cannot receive surgery, left main PCI has significantly advanced, and though the strategy in this scenario remains controversial, double kissing crush stenting<a href="https://solaci.org/en/2019/09/19/dk-crush-is-still-the-best-option/" title="Read more" >...</a>
Results from the BIO-RESORT trial at three years, soon to be published in JACC Intv., show that, despite significant differences among stents as regards strut thickness and capability to reabsorb the polymer, there are no apparent safety or efficacy differences among devices. The aim of this study was to determine the three-year safety and efficacy<a href="https://solaci.org/en/2019/09/18/thin-very-thin-and-ultrathin-struts-with-permanent-or-biodegradable-polymer-which-is-the-best-combination/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Generally, coronary artery dissection (SCAD) is not very frequent in young women and presents better evolution with medical treatment. However, it is occasionally associated with ST segment elevation. In this scenario, PCI with stent implantation is quite challenging. The study looked at 4298 STEMI patients; 53 presented SCAD (1.23%). STEMI-SCAD<a href="https://solaci.org/en/2019/09/17/stemi-in-coronary-dissections-when-should-we-do-it-and-what-are-its-outcomes/" title="Read more" >...</a>
The SYNTAXES (SYNTAX Extended Survival) was presented at ESC 2019 with somewhat unexpected results in favor of PCI. This is why the SYNTAX continues to be one of the best studies interventional cardiologists can rely on. The original SYNTAX tested mortality (primary end point) with PCI vs. CABG in patients with multivessel and/or left main<a href="https://solaci.org/en/2019/09/06/esc-2019-syntaxes-ten-year-outcomes/" title="Read more" >...</a>
In Paris, during the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions, new guidelines for the diagnosis and treatment of chronic coronary syndromes were presented. This document, simultaneously published in Euro Heart J, updates the 2013 guidelines on stable ischemic heart disease and takes out the word “stable” so as to emphasize that the<a href="https://solaci.org/en/2019/09/05/esc-2019-new-european-guidelines-on-chronic-coronary-syndromes/" title="Read more" >...</a>
The use of ticagrelor in patients with stable coronary artery disease significantly reduces the rate of major cardiovascular events when compared against aspirin, according to this study presented on Sunday at ESC 2019 simultaneously published in NEJM, though the cost in terms of major bleeding seems unacceptable. Primary end point rate (composite of cardiovascular death,<a href="https://solaci.org/en/2019/09/03/esc-2019-themis-ticagrelor-in-diabetics-with-stable-coronary-artery-disease/" title="Read more" >...</a>
The American College of Cardiology/American Heart Association (ACC/AHA) have recently published primary prevention cardiovascular disease guidelines. They were originally considered very useful for general practitioners who had no choice but to review separately expert consensus or clinical practice guidelines for hypertension, cholesterol, diabetes, etc. Now, everything is concentrated in a single reference document. But is<a href="https://solaci.org/en/2019/08/13/primary-prevention-guidelines-published-for-the-first-time-are-they-useful-for-all-patients/" title="Read more" >...</a>
A new FDA letter confirms late mortality signal with paclitaxel eluting stents and paclitaxel coated balloons in peripheral territory. Even though this recently published letter confirms data, there are no new recommendations on the use of these devices. After careful consideration of their own analyzis outcomes and a 2-day discussion of an advisory panel especially<a href="https://solaci.org/en/2019/08/12/new-fda-updates-on-paclitaxel-device-outcomes/" title="Read more" >...</a>
For over ten years, SOLACI’s Regional Sessions have set trends in Latin America, promoting medical education, advancing scientific development and research, fostering interventionism’s best practices and organizing scientific events of utmost importance for our specialty in different countries across Latin America and the Caribbean. This is why both SOLACI and SBHCI regard the presence of<a href="https://solaci.org/en/2019/07/26/solaci-sbhci-2019-solacis-regional-sessions-say-here-at-the-annual-meeting/" title="Read more" >...</a>
Prestigious Scientific Societies from all over the world will attend the Congress to discuss the latest advances in interventional cardiology. Discover the International Joint Sessions 01/08 | Paulista Room | 8:30 – 10:00 | Portuguese Society of Cardiology (APIC) Symposium – Acute Coronary Syndrome 8:30 – 8:42 – PCI in NSTEMI ACS: how and when<a href="https://solaci.org/en/2019/07/17/solaci-sbhci-2019-congress-international-joint-sessions/" title="Read more" >...</a>